Bone marrow stroma-secreted cytokines protect JAK2V617F-mutated cells from the effects of a JAK2 inhibitor

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3831-3840

  Manshouri, Taghi ^a   Estrov, Zeev ^a   Quintás Cardama, Alfonso ^a   Burger, Jan ^a   Zhang, Ying ^a   Livun, Ana ^a   Knez, Liza ^a   Harris, David ^a   Creighton, Chad J ^b   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATIPRIMOD; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; NEUTRALIZING ANTIBODY; STAT3 PROTEIN; STAT5 PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL; CELL ASSAY; CELL LINE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG TARGETING; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROENVIRONMENT; MONONUCLEAR CELL; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PARACRINE SIGNALING; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA; STROMA CELL; SUPERNATANT;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOKINES; DRUG RESISTANCE; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; STROMAL CELLS; TRANSFECTION;

EID: 79957923046     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4002     Document Type: Article

References (23)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. (Pubitemid 40386783)
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97. (Pubitemid 40544655)
5. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788-92. (Pubitemid 40853184)
6. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
7. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6.
8. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-30.
9. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52.
10. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
11. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009;23:2233-41.
12. Kawano Y, Kobune M, Yamaguchi M, Nakamura K, Ito Y, Sasaki K, Takahashi S, et al. Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood 2003;101:532-40. (Pubitemid 36077574)
13. Quintas-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, et al. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs 2010 Apr 7. [Epub ahead of print].
14. Verstovsek S, Manshouri T, Quintas-Cardama A, Harris D, Cortes J, Giles FJ, et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 2008;14:788-96. (Pubitemid 351231161)
15. V617F mutation. Exp Hematol 2007;35:32-8.
16. Manshouri T, Quintas-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008;99:1265-73. (Pubitemid 351695096)
17. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyré MC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008;112:3026-35.
18. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007;129:1081-95. (Pubitemid 46908695)
19. Rameshwar P, Chang VT, Gascon P. Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol 1996;93:22-9. (Pubitemid 26130712)
20. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56. (Pubitemid 30339210)
21. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709-15. (Pubitemid 43906643)
22. Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 2006;34: 1617-23. (Pubitemid 44838997)
23. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 2006;55:830-40.